<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903408</url>
  </required_header>
  <id_info>
    <org_study_id>Klaus Tschira 00.153.2009</org_study_id>
    <secondary_id>ARO 2009-05</secondary_id>
    <nct_id>NCT01903408</nct_id>
  </id_info>
  <brief_title>Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment</brief_title>
  <acronym>PLATIN</acronym>
  <official_title>Prostate and Whole Pelvis Irradiation With Integrated-boost Intensity-modulated Radiotherapy (IMRT) After Neoadjuvant Antihormonal Treatment - a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klaus Tschira Stiftung gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with prostate cancer and a high risk of lymph node involvement or confirmed
      pelvic lymph node metastases, radiotherapy of the whole pelvis is a treatment option.
      However, conventional radiotherapy of the pelvis has limited by gastrointestinal and
      urogenital side effects. The PLATIN trial investigates an intensity-modulated radiotherapy of
      the pelvic lymphatic drainage that spares small bowel, bladder and rectum. A higher dose is
      given during each session to the prostate or the prostate bed and to confirmed lymph node
      metastases. Prior to radiotherapy, two months of neoadjuvant antihormonal treatment are
      required, and continuation during radiotherapy and for a further two years are strongly
      recommended.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PLATIN trial is designed as a prospective, non-randomized, five-arm trial. Arm 1:
      Definitive radiotherapy of the pelvic lymphatic drainage with integrated boost to the
      prostate.

      Arm 2: As arm 1, with additional boost to macroscopic lymph node metastases. Arm 3:
      Postoperative radiotherapy of the pelvic lymphatic drainage with integrated boost to the
      prostate bed.

      Arm 4: As arm 3, additional boost to macroscopic lymph node metastases. Arm 5: Patients with
      previous radiotherapy to the prostate bed. Radiotherapy of the pelvic lymphatic drainage
      above the previous treatment fields with integrated boost to macroscopic lymph node
      metastases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of safe feasibility (SDR)</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of treatments begun as planned without grade 3-4 NCI common toxicity criteria adverse events (CTC AE) or treatment disruption among all patients that fulfill inclusion criteria and have been treated according to trial protocol for at least a week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical recurrence free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Boost to prostate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate (76.5 Gy) in 34 fractions Arm finished recruitment and follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Boost to prostate and lymph node metastases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate (76.5 Gy) &amp; pelvic lymph node mets (61.2 Gy) in 34 Fx</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Boost to prostate bed</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate bed (68 Gy) in 34 fractions Arm finished recruitment and follow-up and is published</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Boost to prostate bed and lymph node metastases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate bed 68 Gy) &amp; lymph node metastases (61.2 Gy) in 34 Fx</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Boost to lymph node metastases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with previous irradiation of the prostate bed: IMRT of the pelvic lymphatic drainage (46.8 Gy) above the previous treatment fields, SIB to lymph node metastases (63.2 Gy) in 26 Fx</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB</intervention_name>
    <description>The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)</description>
    <arm_group_label>Arm 1: Boost to prostate</arm_group_label>
    <arm_group_label>Arm 2: Boost to prostate and lymph node metastases</arm_group_label>
    <arm_group_label>Arm 3: Boost to prostate bed</arm_group_label>
    <arm_group_label>Arm 4: Boost to prostate bed and lymph node metastases</arm_group_label>
    <arm_group_label>Arm 5: Boost to lymph node metastases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed prostate cancer with Gleason Score

          -  risk of lymph node involvement &gt;20% (according to Roach Formula), pelvic lymph node
             metastases in CT/MRI or histologically confirmed lymph node involvement

          -  Karnofsky Index &gt;/= 70%

          -  age 18-75 years

          -  neoadjuvant antihormonal treatment for 2 months, continuation until the end of
             radiotherapy

          -  written informed consent

        Exclusion Criteria:

          -  stage IV (distant metastases)

          -  lymph node metastases outside the pelvis

          -  rising prostate-specific antigen (PSA) under antihormonal treatment

          -  severe wound complications after laparatomy

          -  severe lymph edema of the legs, elephantiasis, postthrombotic syndrome

          -  decompensated comorbidity of the lungs, heart, metabolic system, hematopoetic system
             or kidneys, coagulopathy

          -  history of other malignancy within the last 5 years (except for basal cell carcinoma
             or squamous carcinoma of the skin)

          -  previous irradiation of the pelvic lymph nodes

          -  concurrent participation in a clinical trial that might influence the results of
             either trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Herfarth, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg, Department of Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renate Haselmann</last_name>
    <phone>+496221</phone>
    <phone_ext>568202</phone_ext>
    <email>renate.haselmann@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandros Gioules</last_name>
    <phone>+496221</phone>
    <phone_ext>568202</phone_ext>
    <email>alexandros.gioules@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florian Sterzing, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregor Habl, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonja Krause, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Habl G, Katayama S, Uhl M, Kessel KA, Edler L, Debus J, Herfarth K, Sterzing F. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial. BMC Cancer. 2015 Nov 7;15:868. doi: 10.1186/s12885-015-1886-5.</citation>
    <PMID>26547188</PMID>
  </results_reference>
  <results_reference>
    <citation>Katayama S, Habl G, Kessel K, Edler L, Debus J, Herfarth K, Sterzing F. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial. BMC Cancer. 2014 Jan 14;14:20. doi: 10.1186/1471-2407-14-20.</citation>
    <PMID>24422782</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Klaus Herfarth, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

